Dr. Ahmed Salem graduated from Misr University for Science and Technology in Egypt in 2005. He then undertook his postgraduate training in 2008 at the American University of Beirut, Lebanon. He obtained his MSc in Oncology from Newcastle University in the UK in 2013, and in 2014, became a fellow of ESTRO by examination. In parallel, he completed training in radiation oncology at King Hussein Cancer Centre, Amman, Jordan in 2014. He successfully completed the European Society of Medical Oncology (ESMO) examination fellowship and a certificate in 2015, and in the same year, he got MRCP in Medical Oncology from the Royal College of Physicians and FRCR in Clinical Oncology from the Royal College of Radiologists in the UK. In 2017, he completed a clinical research fellowship and attained a Ph.D. in Medicine at the University of Manchester, the UK, for research focusing on non-invasive therapeutic lung cancer biomarkers. Dr. Salem is currently a Senior Clinical Lecturer in Lung Cancer Research at the University of Manchester and an Honorary Consultant in Clinical Oncology at The Christie Hospital, Manchester, UK. He has published many peer-reviewed papers and many abstracts, posters, and proceedings in eminent oncology conferences. His research focuses on proton radiotherapy, MR guided radiotherapy (MR Linac), validating novel biomarkers of hypoxia, and radiosensitivity in lung cancer patients, leading to the conduct of biomarker-driven clinical trials. Dr. Salem is a recipient of more than 10 prestigious academic oncology awards such as the ESTRO Accuray Award in 2018 and the ASTRO International-US annual meeting scientific abstract award. He is a committee member in the Royal College of Radiologists clinical oncology and serves as Director and Chair of the ESTRO FALCON lung cancer contouring workshops operational group.